FIELD: medicine; therapy.
SUBSTANCE: invention relates to the field of medicine, namely to therapy; it is intended for the treatment of Fabry’s disease. For the treatment of Fabry’s disease, a single dosage form is used, containing a human vegetative recombinant α-galactosidase crosslinked using bis-NHS-PEG45. Monomers of the specified human recombinant α-galactosidase are covalently bound to each other by means of a poly(alkylene) glycol binding fragment containing at least 20 alkylene groups. The specified single dosage form is composed in the form of liquid for intravenous injection, and injection is performed at a dose of 2 mg/kg at intervals of 4 weeks.
EFFECT: use of the invention is safe, and it provides significant improvement of patient’s disease parameters in terms of reduction in accumulation of globotriaosylceramide, pain parameters, and gastrointestinal tract, stabilization of kidney and heart functions in clinical conditions.
17 cl, 4 dwg, 3 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| STABILISED ALPHA-GALACTOSIDASE AND USE THEREOF | 2011 |
|
RU2604795C2 |
| METHODS AND COMPOSITIONS FOR TREATING FABRY DISEASE | 2020 |
|
RU2822369C2 |
| METHODS AND COMPOSITIONS FOR THE TREATMENT OF FABRY DISEASE | 2017 |
|
RU2788133C2 |
| TREATMENT OF α-GALACTOSIDASE A INSUFFICIENCY | 2000 |
|
RU2248213C2 |
| INTRAVENTRICULAR DELIVERY OF ENZYMES IN CASE OF LYSOSOMAL STORAGE DISEASES | 2007 |
|
RU2529830C2 |
| INTRAVENTRICULAR DELIVERY OF ENZYMES IN LYSOSOMAL STORAGE DISEASES | 2014 |
|
RU2665381C2 |
| COMPOSITIONS BASED ON SIALYLATED GLYCOPROTEINS AND USE THEREOF | 2015 |
|
RU2689119C2 |
| METHODS AND COMPOSITIONS FOR DELIVERING THERAPEUTIC PROTEIN | 2019 |
|
RU2818779C2 |
| METHODS FOR TREATING INFECTIOUS DISEASES CAUSED BY CORONAVIRUS | 2021 |
|
RU2772701C1 |
| COMPOSITIONS AND METHODS FOR INTERNALIZATION OF ENZYMES | 2018 |
|
RU2806021C2 |
